Artiva Biotherapeutics Raises $ 120 Million in Series B Funding to Advance NK Cell-Based Allogeneic Therapies Pipeline
SAN DIEGO – (COMMERCIAL THREAD) –Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company that develops cell therapies based on natural killer primary allogeneic (NK) cells optimized for their ability to kill tumors, today announced the closing of a round-robin funding B of $ 120 million. New investor Venrock Healthcare Capital Partners led the funding. Other new investors participating in the funding included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel Company), Wellington Management Company and a non-leading disclosed global investment firm. Existing investors, 5AM Ventures, RA Capital Management and venBio Partners, as well as strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX: 005250), also participated in the financing. Artiva plans to use the proceeds of the funding to advance its NK cell therapy development programs and expand ongoing research and development activities.
“The quality and support of the investor groups participating in this funding further validates the promise of our manufacturing first strategy, the potential of our NK cell platform, and our goal of providing safe, effective and truly cell therapy treatments. ready-to-use products that are immediately accessible to cancer patients, ”said Fred Aslan, MD, CEO of Artiva. “I would also like to welcome Bong Koh to our Board of Directors and look forward to leveraging his expertise as we continue to advance our clinical and other development activities.
“Artiva is a promising company with differentiated technology, strong manufacturing capabilities and a talented management team, ”said Bong Koh, MD, at Venrock Healthcare Capital Partners. “I look forward to working closely with the Board of Directors and management of Artiva during this exciting time of growth for the company.
Artiva cell therapies are designed to take advantage of the innate anti-tumor biology and safety characteristics of NK cells. Therapies are optimized for targeted anticancer activity through CAR or enhancement of ADCC through combination therapy of therapeutic antibodies or innate cell engagement. Artiva’s manufacturing platform supports the large-scale production and cryopreservation of out-of-the-box NK cell allogeneic therapies, as well as proprietary CAR-NK and NK gene editing technologies to increase l therapeutic activity.
About Artiva Biotherapeutics
Artiva’s mission is to provide cancer patients with highly effective, safe and immediately accessible cellular immunotherapies. Artiva’s pipeline includes AB-101, an ADCC-enhancing NK cell therapy for use in combination with monoclonal antibodies or innate cell activators. The company is currently advancing a phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B lymphomas. The Company’s CAR-NK programs include AB-201, a novel HER2-specific CAR-NK cell therapy for the treatment of HER2 + solid tumors, and AB-202, a CD19-specific CAR-NK cell therapy for the treatment of cells B. malignancies, which are under development under Artiva’s master license and option agreement with GC LabCell Corporation, with plans to enter clinical trials in 2022. The company has entered into therapeutic collaborations on NK cells and / or licensing agreements with Merck and with the NK cell of Affimed NV Artiva The platform integrates an expansion, activation and cell engineering technology developed by the commercial partner of the company, GC LabCell, a member of the GC family of companies, one of the leading biopharmaceutical groups in the Republic of Korea. Artiva is headquartered in San Diego. For more information on Artiva Biotherapeutics, please visit www.artivabio.com.